On January 27, Suzhou AlphaMa Biotechnology Co., Ltd. (hereinafter referred to as "AlphaMa") and Suzhou Institute of Drug Innovation Shanghai Institute of Materia Medica (hereinafter referred to as "SUSIMM") signed a strategic alliance agreement with Hefei KS-V Peptide. AlphaMa and KS-V Peptide's representatives signed the "DEL Technology-based Artificial Intelligence Boosted Drug Screening Collaborative Agreement" on the afternoon of January 27.…
2021/01/29
AlphaMa will cooperate with Viva Biotech to provide clients AI-based DNA Encoded compound library screening technology. SHANGHAI, CHINA----Recently, AlphaMa Biotech signed a new drug discovery technology cooperation agreement with Viva Biotech Co., Ltd. (hereinafter referred to as " Viva"). According to the agreement, AlphaMa will cooperate with Viva Biotech on innovative drug discovery technology to provide clients with the new…
2020/12/21
On December 14, 2020, Simcere Pharmaceutical Co., Ltd. (Simcere) and AlphaMa Biotechnology Co., Ltd. (AlphaMa) signed a strategic partnership agreement for new drug discovery. According to the agreement, AlphaMa will use artificial intelligence (AI) technologies and design, synthesis, and screen technologies of DNA Encoded Library (DEL) to screen the lead compounds of a series of specific targets in the field…
2020/12/15
Alphama PatMap patent analysis platform is online！
PatMap patent analysis software has been launched
Simcere Pharmaceuticals and AlphaMa Biotech signed an exclusive license agreement for the new anti-tumor drug ALM005
AlphaMa and Lilly Collaborate on Drug Discovery Based on Intelligent DNA-Encoded Libraries
AlphaMa & SIMM Joint Team Won the Champion of the International Molecular Translation Challenge
